―New State-of-the-Art Facilities Will Triple the Company’s Space and Greatly Increase Its Manufacturing Capacity for APIs for Clinical Trial Materials and Ultimately Commercial Production―
EUGENE, Ore.–(BUSINESS WIRE)–#cascadechemistry—Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organization, today announced initiation of construction of new facilities designed to increase the company’s capacity to manufacture APIs (active pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures).
The new facilities, expected to be operational in the first quarter of 2022, will ultimately increase the company’s floor space almost three-fold and significantly add to its cGMP manufacturing capacity and scale. The expansion also includes 2,200 square feet of new analytical labs, a robust quality system and additional office space.
“This $14 million expansion reflects our growing success as a reliable, experienced and flexible outsourcing partner with exceptional chemistry problem-solving expertise,” said Jeremiah Marsden, PhD, President of Cascade Chemistry. “Our customers are increasingly requesting our assistance in producing APIs for their clinical trials, and demand has outstripped our cGMP manufacturing capacity. We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”
The 28,000-square-foot building currently under construction will initially include five suites for Phase 1 and Phase 2 cGMP manufacturing with flow hydrogenation and reactors up to 400 liters. Additional capacity for API Phase 3 and commercial scale cGMP manufacturing up to 1,000 liters will be added in 2022. The second building, with 7,000 square feet, is reserved for future expansion.
Dr. Marsden continued, “We ultimately will expand into the second new building to build further cGMP capacity for commercial-stage low-volume, high-value pharmaceuticals. We are grateful for the support from our customers that is driving this expansion, as well as our employees’ dedication to excellence and their creativity and hard work that make it all possible.”
Cascade Chemistry Is Hosting a New Facility Groundbreaking:
Friday, February 19 at 12 noon PT
Cascade Woodruff Site, Building #1
90454 Woodruff Street
About Cascade Chemistry
Cascade Chemistry specializes in active pharmaceutical ingredient (API) process development, scale-up and cGMP (current Good Manufacturing Practices) manufacturing. Most of our chemists have advanced degrees and are capable of crafting process solutions tailored to the specific needs of our clients, while adhering to strict FDA quality standards. We offer cost effective and rapid solutions for the development and manufacturing of API cGMP batches at 1-10 kg scale, and we will begin offering greater capacity at our new facility in 2022. It has been our philosophy for almost 40 years that quality is a key component of successful cGMP manufacturing. We view quality as a guiding principle, achieved by rigorous due diligence at each step of the development and manufacturing process. Cascade Chemistry is headquartered in Eugene, Oregon. For more information, visit www.cascadechemistry.com.
Director of Business Development